Satellos Bioscience Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-9.3%projected annual EPS growth
Analyst Coverage
3analysts covering
FY EPS (est.)
-$2.40next fiscal year
Monitoring Framework
Key Performance Indicators
BASECAMP Clinical Trial Enrollment Progress QuarterlyTarget: Complete enrollment of 51 ambulatory boys with DMD
TRAILHEAD Clinical Trial Enrollment Progress QuarterlyTarget: Enroll up to 30 individuals living with DMD aged 16 to 25
Cash Runway Quarterly69.9MTarget: Fund operations and milestones through 2027
Watch Items
- BASECAMP Enrollment CompletionTrigger: Q3 2026Action: Verify if enrollment is completed on schedule to maintain clinical timelines.
- TRAILHEAD 6-Month Interim DataTrigger: Q2 2026Action: Monitor for long-term safety, efficacy, and sustained functional benefit of SAT-3247 in adults.
- Preclinical Expansion into FSHDTrigger: Ongoing 2026Action: Track regulatory filings or clinical trial initiations for SAT-3247 in facioscapulohumeral muscular dystrophy.
Research as of 19 Jun 2026